Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR1E | P28566 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352034 | 0.83 | ALDH1A1 (0.34) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11319869 | 0.81 | KDM4E (0.33) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL127488 | 0.81 | TSHR (0.38) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11029404 | 0.79 | KDM4E (0.33) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9501246 | 0.78 | OPRK1 (0.36) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6528243 | 0.78 | OPRK1 (0.38) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL213436 | 0.75 | ALDH1A1 (0.35) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2699253 | 0.75 | ALDH1A1 (0.35) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7549527 | 0.73 | TSHR (0.43) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20656 | 0.73 | TSHR (0.43) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730148-A4 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LAB (US) | 2009-08-19 | — | — | EP | claimed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | claimed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | claimed |
| EP-1244679-A1 | PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20020068721-A1 | Purine derivatives | ARIAD PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2001044259-A1 | PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| EP-0979228-A4 | NOVEL CANNABINOID RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-05-03 | — | — | EP | claimed |
| EP-0979228-A1 | NOVEL CANNABINOID RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-16 | — | — | EP | claimed |
| US-5948777-A | ANTIINFLAMMATORY AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-07 | — | — | US | claimed |
| WO-1998041519-A1 | NOVEL CANNABINOID RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-24 | — | — | WO | claimed |
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | claimed |
| US-5677283-A | α-heteroaryloxymethyl ketones as interleukin - 1 β converting enzyme inhibitors | SANOFI (FR) | 1997-10-14 | — | — | US | claimed |
| EP-0644198-A1 | Alpha-heteroaryloxymethyl ketones as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | claimed |
| EP-0644197-A1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | claimed |
| EP-0121171-B1 | FUNGICIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1989-05-10 | — | — | EP | claimed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | claimed |
| EP-0121171-A2 | Fungicides, process for their preparation and their use | BAYER AG (DE) | 1984-10-10 | — | — | EP | claimed |
| EP-0105166-A1 | Substituted tert. butanol derivatives, method for their preparation and antimycotic agents containing them | BAYER AG (DE) | 1984-04-11 | — | — | EP | claimed |
| US-4442119-A | Cyclopropyl analogs as estrogenic and anti-fertility agents | THE BOARD OF REGENTS FOR THE UNIVERSITY OF OKLAHOMA (US) | 1984-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | KDM4E 403/4885KMT2A 261/4885MEN1 2995/4885 |
| US-20020068721-A1 | Purine derivatives | HPRT1, PNP, TYMP | KDM4E 3459/4885KMT2A 3294/4885MEN1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.